GBT to Announce Third Quarter 2020 Financial Results on Thursday, November 5, 2020
October 29 2020 - 8:00AM
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today
announced that it will report third quarter 2020 financial results
on Thursday, November 5, 2020, after U.S. financial markets close.
Management will host a conference call on Thursday, November 5,
2020, at 4:30 p.m. ET to provide a general business update and to
discuss third quarter 2020 financial results. To participate in the
conference call, please dial 877-252-3031 (domestic) or
312-281-1210 (international). A live audio webcast of the
conference call can be accessed on GBT’s website at www.gbt.com
under the Investors section. An archived audio webcast will be
available for one month following the event.
About Global Blood TherapeuticsGlobal Blood
Therapeutics (GBT) is a biopharmaceutical company dedicated to
the discovery, development, and delivery of life-changing
treatments that provide hope to underserved patient communities.
Founded in 2011, GBT is delivering on its goal to transform the
treatment and care of sickle cell disease (SCD), a lifelong,
devastating inherited blood disorder. The company has introduced
Oxbryta® (voxelotor), the first FDA-approved treatment that
directly inhibits sickle hemoglobin polymerization, the root cause
of red blood cell sickling in SCD. GBT is also advancing its
pipeline program in SCD with inclacumab, a p-selectin inhibitor in
development to address pain crises associated with the disease. In
addition, GBT’s drug discovery teams are working on new targets to
develop the next generation of treatments for SCD. To learn more,
please visit www.gbt.com and follow the company on
Twitter @GBT_news.
Contact Information:Steven Immergut (investors
and media)650-410-3258simmergut@gbt.com
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Global Blood Therapeutics (NASDAQ:GBT)
Historical Stock Chart
From Sep 2023 to Sep 2024